3Ware IE Jr, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment(IQOLA)project. J Clin Epide- miol, 1998, 51(11): 903-912.
4Sehipper H, Clinch J, McMurray A, et al. Measuring the quality of Life of cancer patients: the functional living index: development and validation. Journal of Clinical Oncology, 1984, 54(32): 472-483.
5Wan C, Fang J, Yang Z, et al. Development and validation of a qual-I ity of life instrument for patients with liver cancer QOL-LC. Am Clin Oncol, 2010, 33(5): 448-455.
6Wan C, Fang J, Yang Z, et al. Development andvalidation of a qual- ity of life instrument for patients with liver cancer QOL-LC. Am J Clin Oncol, 2010, 33(5): 448-455.
7Heffernan N, Celia D, Webster K, et al. Measuring Health-Related Quality of Life in Patients With Hepatobiliary Cancers: ~he Func- tional Assessment of Cancer Therapy-Hepatobiliary Questionnaire. Journal of Clinical Oncology, 2002, 20(9): 2229-2239.
8Hobson P, Bhowmick B, Meara J, et al. Use of the SF-36 question- naire in cerebrovascular disease. Stroke, 1997, 28(2): 464-465.
9Wible BC, Rilling WS, Drescher P, et al. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary, transarterial chemoembolization.J Vasc Interv Radiol, 2010, 21(7): 1024-1030.
10Fan SY, Eiser C, Ho MC. Health-related quality of life in patients with hepatocellular carcinoma: a systematic review. Clin Gastroen. terol Hepatol, 2010, 8(7): 559-564.
